Skip to content

Testing the safety of test products by placing patches on healthy volunteers for 24 hours, keeping the patches covered completely.

Evaluation of dermatological safety of investigational products by 24hrs patch test under complete occlusion on healthy human subjects - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/075037
Enrollment
24
Registered
2024-10-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Line-Tune Peptide-Plump Fluid: 40 microlitre of investigational product with or without dilution (as per the protocol) will be applied back side of the subject. Dose- 40 Microlitre

Sponsors

Transformative Learning Solution Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects in age group 18 - 65 years (both the ages inclusive). Healthy male & female subjects with skin types as defined in the population details under appendix 1. Subjects in good health condition as per the medical screening criteria with no disease state or physical condition that the Investigator believes could interfere with the interpretation of the data. Subject able to read, understand and sign an appropriate informed consent form indicating their willingness to participate. Subjects willing to maintain the patch test in position for 24 hours. Subjects willing to come for regular follow-up visits. Subjects ready to follow instructions during the study period.

Exclusion criteria

Exclusion criteria: Subjects with infection or any skin indications at the test area i.e. back of the subjects. Subjects with known history of skin allergy, antecedents or atopic subjects. Athletes and subjects with history of excessive sweating. Subjects with cutaneous disease which may influence the study result. Subjects on oral corticosteroid. Subjects participating in any other cosmetic or therapeutic trial. Subjects who are pregnant or nursing (self-declared). Subjects with any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness. Subjects working with MSCR.

Design outcomes

Primary

MeasureTime frame
to determine the potential irritation of the test formulation in different skin types in a PIPT test.Timepoint: 0Hrs,24hrsand Day7

Secondary

MeasureTime frame
NATimepoint: NA

Countries

India

Contacts

Public ContactRadha S

Transformative Learning Solution Pvt. Ltd.

mukta.sachdev@msclinical.com9891253516

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026